GlassScriptPhysician profile
Timothy T Wellemeyer
NPI 1407814916
$3,451.33
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $904 · 2021: $871 · 2022: $530 · 2023: $288 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.14 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $448.89 | 2019-2022 | |
| Abbvie INC. | $267.01 | 2020-2024 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $263.17 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $210.42 | 2020-2023 | Emgality, Jardiance |
| Pfizer INC. | $209.10 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.57 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $131.10 | 2019-2021 | |
| Amarin Pharma, INC. | $125.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.65 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $98.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.07 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.14 | 2022 | |
| Hologic Sales and Service, LLC | $69.93 | 2020 | |
| Allergan, INC. | $69.46 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $66.24 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $52.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $52.34 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.82 | 2021 | |
| Merck Sharp & Dohme LLC | $37.95 | 2019-2021 | |
| Radius Health, INC. | $32.99 | 2019-2024 | Tymlos |
| Eisai INC. | $30.80 | 2021 | |
| Adlon Therapeutics L.P. | $29.13 | 2020-2021 | |
| Shire North American Group INC | $26.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.84 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.26 | 2023 | Eliquis |
| Clarus Therapeutics INC. | $17.87 | 2021 | |
| Exact Sciences Corporation | $17.41 | 2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $15.80 | 2021 | |
| Sumitomo Pharma America, INC. | $15.44 | 2024 | Gemtesa |
| Astellas Pharma US INC | $15.26 | 2020 | |
| Harmony Biosciences LLC | $15.05 | 2020 | |
| Esperion Therapeutics, INC. | $14.70 | 2021 | |
| Bardy Diagnostics, INC. | $14.57 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.85 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.41 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wellemeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.